StocksMedium•4 November 2026•
1 min read
Precigen Reports $35.8M Q3 Net Income Driven by PAPZIMEOS Revenue Surge
Key Facts
1Precigen reported net income of $35.8 million for the third quarter of 2026.
2PAPZIMEOS net revenue rose 37% quarter-over-quarter to $72.9 million.
3The company achieved positive cash flow one full quarter ahead of previous guidance.
Precigen reported net income of $35.8 million for the third quarter of 2026, according to a statement released via PR Newswire. Net revenue for the drug PAPZIMEOS rose 37% quarter-over-quarter to $72.9 million, enabling the company to achieve positive cash flow one full quarter ahead of its previous guidance.
PGEN closed at $5.25 on November 3, 2026, having traded between a low of $5.06 and a high of $5.38 during that session. The financial results were driven by robust commercial adoption of PAPZIMEOS in the U.S. and the receipt of FDA Platform Technology Designation for the company's AdenoVerse platform.